Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson sPRAVATO (esketamine) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
1,485
Period ended Dec 28, 2025
Change on a year earlier
+59.8%
929 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SPRAVATO (esketamine) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 1,485 | +59.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 929 | +57.7% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 589 | +79.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 328 | – | Form 10-K (filed 2025-02-13) ↗ |
Breakdown
What makes up spravato (esketamine) — u.s. sales ($m)
Cite this data
StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) — U.S. sales ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_spravato_us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.